Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6365768
Interleukin-1 and tumor necrosis factors-&agr; modulators, syntheses of said modulators and methods of using modulators
expired -
US 6365164
Use of neurotoxin therapy for treatment of urologic and related disorders
expired -
US 6365359
Inhibitors of prion formation
expired -
US 6365138
Compositions for metabolic protection and repair of lips
expired -
US 6365401
Method and probes for the identification of microbial genes specifically induced during host infection
expired -
US 6362322
Conversion of a watson-crick DNA to a hoogsteen-paired duplex
expired -
US 6362200
Antitumor dibenzofluorene derivatives
expired -
US 6359158
Methods and products related to 16-HETE analogs
expired -
US 6358523
Macromolecule-lipid complexes and methods for making and regulating
expired -
US 6355270
Particles for oral delivery of peptides and proteins
expired -
US 6355619
Peptide tumor cell growth inhibitors
expired -
US 6355255
Streptococcal C5a peptidase vaccine
expired -
US 6355440
Assays using receptors for fibroblast growth factors
expired -
US 6355790
Inhibition of HIV replication using a mutated transfer RNA primer
expired -
US 6353151
Transgenic model for heart failure
expired -
US 6352694
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
expired -
US 6352991
2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
expired -
US 6350729
Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
expired -
US 6350769
Gaba alpha receptors mediate inhibition of T cell responses
expired -
US 6350593
Receptors for fibroblast growth factors
expired -
US 6350479
Treating depression with alcohol extracts of tobacco
expired -
US 6348493
Treatment and prevention of hepatic disorders
expired -
US 6346607
APAF-1 an activator of caspase-3
expired -
US 6346411
DNA encoding—candida albicans integrin-like protein
expired -
US 6344548
Diacylglycerol o-acyltransferase
expired -
US 6344544
Semaphorin-specific antibodies
expired -
US 6344554
Polynucleotide sequences from Candida albicans encoding polypeptides associated with filamentous growth
expired -
US 6342216
Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
expired -
US 6342501
Pyrrolo[2,3-d] pyrimidines as antiviral agents
expired -
US 6342595
Oncoprotein protein kinase
expired -
US 6342484
Method and compositions for promotion of wound treatment
expired -
US 6342351
Methods and compositions for diagnosing and treating chromosome-18p related disorders
expired -
US 6342219
Antibody compositions for selectively inhibiting VEGF
expired -
US 6342221
Antibody conjugate compositions for selectively inhibiting VEGF
expired -
US 6340743
Antibodies to PIGR stalk
expired -
US 6337206
Nucleic acid encoding mouse galanin receptor (GALR2)
expired -
US 6335010
Gene therapy in coronary angioplasty and bypass
expired -
US 6335180
Nucleic acid sequences encoding capsaicin receptor and uses thereof
expired -
US 6335318
Antimicrobial theta defensins and methods of using same
expired -
US 6333313
Clinical use of oxytocin alone or in combination to treat bone disorders
expired -
US 6333172
Genes and proteins controlling cholesterol synthesis
expired -
US 6333033
Autoantibody inhibitors
expired -
US 6331409
Methods and compositions for wound healing
expired -
US 6331284
P202 is a tumor suppressor
expired -
US 6331555
Treatment of platelet derived growth factor related disorders such as cancers
expired -
US 6329357
Therapeutically effective 1.alpha., 25-dihydroxyvitamin D3 analogs and methods for treatment of vitamin D diseases
expired -
US 6329368
Endocrine modulation with positive modulators of AMPA type glutamate receptors
expired -
US 6326356
Suppression of neu overexpression using a mini-E1A gene
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory